AzTrials
AzTrials

End Stage Renal DiseaseNCT03389932

Explore Transplant @Home Within Kaiser Permanente Southern California

A study testing Patient-Guided in people with End Stage Renal Disease, run by The Methodist Hospital Research Institute at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Today, there are 25 million Americans with chronic kidney disease (CKD) and 660,000 patients in full kidney failure, the final CKD stage, known as end stage renal disease (ESRD). Over half of ESRD patients are Black, Hispanic, or Asian. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
End Stage Renal Disease
What is being tested?
Patient-Guided
Could I receive a placebo?
No, everyone receives an active treatment
How many people
977 participants
Where
1 siteUnited States
Study dates
11 Jul 2018to 31 Dec 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Participant must be at least 18 years of age.
  • Participant must self-identify as African American, White, Hispanic, or Asian.
  • Participant must currently be classified as having CKD 3, 4 or 5.
  • Participant must be able to speak and read in English or Spanish.

Who cannot join

  • Participant is not classified as having CKD 3,4, or 5.
  • Participant cannot speak or read in English or Spanish.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Kaiser Permanente Research and Evaluation

    Pasadena, California, 91101

Other trials in United States

About this study

Official title: Working Within an Integrated Learning Healthcare System to Improve Living Kidney Donation Knowledge Across the CKD Continuum for All Racial Groups

Today, there are 25 million Americans with chronic kidney disease (CKD) and 660,000 patients in full kidney failure, the final CKD stage, known as end stage renal disease (ESRD). Over half of ESRD patients are Black, Hispanic, or Asian. ESRD patients must either receive regular dialysis treatments, by which waste is filtered from the blood by a machine, or a kidney transplant from a deceased or living donor. Five-year survival on dialysis is only 40%, compared to 74% with a deceased donor kidney transplant (DDKT) and 87% with a living donor kidney transplant (LDKT). Despite the known health benefits of DDKT and LDKT, 70% of ESRD patients remain on dialysis, especially ethnic/racial minorities.

An American Society of Transplantation (AST) Consensus Conference recently recommended that patients in all CKD stages should have the opportunity to learn about and decide which treatment option is right for them, particularly about LDKT. However, early education about LDKT and DDKT is inconsistent and often poor, with early stage CKD patients and ethnic/racial minorities even less likely to receive it.

Through previous HRSA grants, Dr. Waterman designed the Explore Transplant@Home (ET@Home) video-guided education program, and found that it significantly increased LDKT knowledge and informed decision-making for Black and White dialysis patients in Missouri when delivered by mail and supported through bimonthly postcards and texting. Now based at the University of California, Los Angeles (UCLA), she has partnered with Kaiser Permanente Southern California (KPSC), an integrated learning healthcare system providing insurance coverage and comprehensive care to 65,000 patients in CKD Stages 3, 4 and 5 (ESRD) (24% Hispanic, 52% White, 15% Black, and 9% Asian; 10% Spanish-speaking).

Read the detailed description

Today, there are 25 million Americans with chronic kidney disease (CKD) who are at risk for kidney failure and 660,000 patients with end-stage renal disease (ESRD). To sustain life, ESRD patients, among whom 31% are Black, 15% are Hispanic, and 5% are Asian, must either receive daily or weekly dialysis treatments, by which waste is filtered from the blood by a machine, or receive a kidney transplant from a deceased or living donor. Five-year survival for patients on dialysis is only 40%, compared to 74% for patients who receive a deceased donor kidney transplant (DDKT) and 87% for patients who receive a living donor kidney transplant (LDKT)1. Patients who receive kidney transplants live 5-15 years longer than if they remained on dialysis, and have a better health-related quality of life (HRQOL), including a greater likelihood of being in the workforce during their critical earning years2. While LDKT is the medically optimal and most cost effective renal replacement therapy (RRT) for patients with ESRD, LDKT rates have declined by 17% from 2004-2014. In 2014, in the U.S., 17,106 patients received a transplant (5,536 LDKTs) while 8,021 patients also died or became too ill to remain on the list, 70% of whom were racial/ethnic minorities. Of the 2,039 transplants performed in California in 2014, only 595 were from living donors (OPTN data as of 12/11/2015).

Since kidneys often fail slowly over months or years, a patient's level of kidney function is monitored over time as it decreases in nephrologists' offices nationwide. As recommended by a recent American Society of Transplantation (AST) Consensus Conference, all patients in Stage 3 (Moderate CKD), Stage 4 (Severe CKD), or Stage 5 (End Stage CKD) should receive comprehensive education about DDKT and LDKT, especially racial/ethnic minorities. Once patients reach ESRD and begin dialysis, established CKD and Centers for Medicare and Medicaid Services (CMS) guidelines recommend that dialysis patients be educated about their RRT options, the medical risks involved, and the advantages to transplant so that they can make informed RRT decisions4. Since transplants received within the first 6 months of beginning dialysis result in the best health outcomes,5 one Healthy People 2020 goal is to, "Increase the proportion of dialysis patients wait-listed and/or receiving a deceased donor kidney transplant within one year of ESRD start (among patients under 70 years of age)." Unfortunately, research has shown that many patients in CKD clinics are inconsistently educated about LDKT, particularly patients who are socioeconomically disadvantaged or members of racial/ethnic minority groups.

Without a nationally-coordinated healthcare system, it is extremely difficult to ensure that kidney patients in Stages 3-5 who are served by different health practitioners and organizations all learn about DDKT and LDKT and make informed treatment decisions. Providers also report having limited time to educate about transplant outside of transplant centers and inadequate educational materials. Thus, disseminating transplant education within a large health care system, with its fully integrated care management program, diverse membership, and ability to track a large patient population across the entire course of their kidney disease, may be an opportune way to educate large numbers of diverse patients about the opportunities for and risks and benefits of living kidney donation.

Kaiser Permanente Southern California (KPSC) is a large, integrated healthcare system providing coverage and care to over 4 million members throughout Los Angeles, San Diego,Kern, San Bernardino, Riverside, and Ventura Counties. KPSC provides coverage to nearly 65,000 patients with CKD stages 3-5. About 24% of these patients are Hispanic, 52% White, 15% Black, and 9% Asian, similar to the broader CKD population in California.

First, this team will conduct extensive qualitative and quantitative formative research to understand and compare the knowledge, informed decisionmaking and educational needs of these diverse patient groups prior to intervention. Second, they will design a Spanish-language version of ET@Home. Third, they will conduct a randomized controlled trial (RCT) of 1,200 Black, Hispanic, Asian, and White patients in CKD Stages 3-5 where patients will be randomized to receive: (1) no additional education other than what is provided within KPSC (standard-of-care); or (2) a video-guided, four-part ET@Home program delivered by mail and supported through bimonthly postcards and texting over six months. The study aims and hypotheses are as follows: Aim 1: Using qualitative methodology, to assess the LDKT educational needs of CKD Stage 3-5 patients and their support networks by race/ethnicity and primary language spoken.

Hypothesis 1: CKD Stage 3-5 patients and their support networks will have varying needs for educational content about LDKT based on their race/ethnicity and primary language spoken.

Hypothesis 2: Providers will identify important patient needs for LDKT educational content and opportunities for improvement within the KPSC transplant educational system.

Aim 2: Before intervention, to assess differences in knowledge and decision-making about the opportunities for and risks and benefits of living kidney donation for 1200 CKD Stage 3-5 patients by race/ethnicity and primary language spoken.

Hypothesis: Patients earlier in the CKD continuum, patients who speak Spanish, and non- White patients will have less knowledge about the opportunities for and risks and benefits of living kidney donation and will be making less informed LDKT decisions.

Aim 3: Compared to KPSC education, to conduct a randomized controlled trial in English and Spanish of ET@Home for CKD Stage 3-5 patients to assess its effectiveness to increase LDKT knowledge and decision-making by race/ethnicity and primary language spoken.

Hypothesis 1: At the conclusion of the trial, CKD patients who receive ET@Home will have greater transplant knowledge and be more likely to make an informed treatment decision than patients receiving KPSC education alone.

Hypothesis 2: ET@Home will be more or equally effective for patients earlier in the CKD continuum, patients who speak Spanish, and non-White patients than patients in these subgroups receiving KPSC education alone.

Being tested
Patient-Guided
Medical subject headings
Kidney Failure, Chronic

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Patient-GuidedBehavioural

    Patients in the ET@Home study condition will receive four modules of video and print transplant education over a 6-month period. After each module is mailed, 3 postcards are mailed weekly that recap important transplant educational content covered within the videos. Patients will have the opportunity to participate in a texting component of ET@Home that also sends small pieces of educational content and learning reminders by phone each week.

Study groups in NCT03389932
Study groupRoleWhat they receive
Standard of Care (Control)No interventionFor patients who are randomized to the control condition and who are or become potentially eligible for transplant during their enrollment in the study, they will not receive any additional interventions during the study period. Patients in this condition will only receive the education that is administered by the KPSC Kidney Transplant Program and will not receive any educational materials designed for the intervention group of this study.
Patient-GuidedExperimentalPatients in the ET@Home study condition will receive four modules of video and print transplant education over a 6-month period. After each module is mailed, 3 postcards are mailed weekly that recap important transplant educational content covered within the videos. Patients will have the opportunity to participate in a texting component of ET@Home that also sends small pieces of educational content and learning reminders by phone each week.
Receives: Behavioral: Patient-Guided

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Deceased Donor Kidney Transplant (DDKT) and Living Donor Kidney Transplant (DDKT) Knowledge

    Patients will be asked true/false and multiple choice questions to determine their level of knowledge regarding basic facts, advantages, risks and outcomes of DDKT and LDKT (e.g., "Patients older than 75 years can receive transplants"; "Compared to transplants from donors who have died, how long do transplants from living donors last?"). Scores for this scale are created by summing the number of correct answers given by the patient, creating a theoretical range of 0-25 with higher scores indicating more knowledge.

    Measured: 6 months

Secondary outcomes (2)
  1. Decisional Balance

    Decisional Balance will be measured for DDKT (DB-DDKT) and for LDKT (DB-LDKT). DB-DDKT, a measure of a patient's perception of the benefits and disadvantages of deceased donor kidney transplant. This measure has been validated in a sample of dialysis patients84. Both measures contain two subscales, Pros and Cons of 6 items, wherein patients rate the importance of a specific Pro or Con to their DDKT or LDKT decision-making (e.g., "I would not have to be on dialysis") on a Likert-type scale from (1) "Not important" to (5) "Extremely important". Scores for the subscales will be obtained by summing the patients' responses to the items, implying a theoretical range of 6-30, with higher scores indicating more Pros or Cons, depending on the subscale. The DB-LDKT was also recently validated in a sample of dialysis patients.

    Measured: 6 months

  2. Informed Decision-Making

    Informed Decision-Making will be assessed in two ways. First, patients will be asked the following three questions: "I have all the facts I need to make an informed decision about whether to pursue DDKT/LKDT/remain on dialysis" (agree/disagree). Each of these questions will be treated as individual items and analyzed separately as outcomes.

    We will also use a validated measure of decisional conflict, the Decisional Conflict Scale (DCS). This scale assesses factors contributing to patients' uncertainty in making health-related decisions, and patients' assessment of their perceived effective decision-making. Each of these dimensions of decisional conflict will be considered as subscales, and together they will be considered as a total decisional conflict measure. The entire scale has 16 items (3 for decision uncertainty, 9 for factors contributing to uncertainty, and 4 for effective decision-making), each measured on a scale of (1) strongly agree to (5) strongly disagree.

    Measured: 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Jan 2018
  2. Study start11 Jul 2018
  3. Primary completion31 May 2020
  4. Study completion31 Dec 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Health services research
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
977 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03389932
Sponsor's protocol ID
R39OT29879
Status last verified
May 2025
First submitted
26 Dec 2017
Last updated
22 May 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Waterman AD, Anderson C, Alem A, Peipert JD, Beaumont JL, Henry SL, Dub B, Ambriz L, Bijjala N, Lipsey AF, Mittman B. A randomized controlled trial of Explore Transplant at Home to improve transplant knowledge and decision-making for CKD 3-5 patients at Kaiser Permanente Southern California. BMC Nephrol. 2019 Mar 4;20(1):78. doi: 10.1186/s12882-019-1262-9.

    PubMed 30832619

Questions about this trial

What is this clinical trial studying?

A study testing Patient-Guided in people with End Stage Renal Disease, run by The Methodist Hospital Research Institute at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 22 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Deceased Donor Kidney Transplant (DDKT) and Living Donor Kidney Transplant (DDKT) Knowledge (time frame: 6 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03389932, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 May 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in